Although erythropoietin stimulating agents (ESAs) were considered a rational therapy to increase hemoglobin and to treat anemia in CKD patients with HF, these agents do not improve outcomes and may be associated with thromboembolic complications. This evidence concerns the gene EPO and anemia (phenotype).